Loading stock data…
Vaxcyte (PCVX)
$57.72+1.20 (+2.12%)
After Hours$57.72+0.00 (+0.00%)· Last close Jun 29
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vaxcyte, Inc. in the Healthcare sector is trading at $57.72 with a market capitalization of $7.1B. Wall Street consensus targets $109.00 (9 analysts), implying a +88.8% move over the next 12 months. The stock is currently 11% below its 52-week high of $65.00, remaining 16.1% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +88.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$345.85M↓ | -$274.28M↓ | -$242.38M↓ | -$226.22M↓ | -$180.79M |
| Net Income | -$320.62M↓ | -$246.51M↓ | -$212.83M↓ | -$166.57M↓ | -$140.72M |
Peer Comparison
JNJUNHPFE
Fundamentals
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.59%
Volume
Today's trading volume
2.69M
Recent News
Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine
Vaxcyte, Inc. (NASDAQ:PCVX) is one of the most promising healthcare stocks according to Wall Street analysts. On June 2, Vaxcyte, Inc. (NASDAQ:PCVX) dosed the first participant in its Phase 1 first-in-human clinical trial of VAX-A1. VAX-A1 is the company’s experimental vaccine against Group A Streptococcus, or Group A Strep. The dosing marks Vaxcyte’s entry of […]
Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study
Vaxcyte Inc. (NASDAQ:PCVX) is one of the 10 best mid-cap stocks that could double your money. On June 3, Vaxcyte Inc. (NASDAQ:PCVX) announced that the first participant was dosed in the Phase 1, first-in-human study evaluating VAX-A1. This is the company’s investigational prophylactic vaccine candidate for the prevention of disease caused by Group A Streptococcus […]
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial Enrollments
Vaxcyte recently completed enrollment for three Phase 3 adult clinical trials of its VAX-31 pneumococcal vaccine candidate, along with a Phase 2 VAX-31 infant study, and outlined plans to start a Phase 1 adult trial for its VAX-A1 Group A Strep program. This clustering of late- and mid-stage trial milestones highlights how quickly Vaxcyte is moving multiple vaccine candidates toward potential regulatory review and future commercialization decisions. We’ll now explore how completing...
Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials
Vaxcyte Inc. (NASDAQ:PCVX) is one of the best mid cap stocks to buy with highest upside potential. On May 6, Vaxcyte achieved a significant milestone by completing enrollment for its three Phase 3 adult clinical trials (OPUS-1, OPUS-2, and OPUS-3) evaluating VAX-31 for the prevention of invasive pneumococcal disease. The OPUS-1 study serves as a […]